Pular para o conteúdo principal
Ranking Invest

LEGN - Legend Biotech Corporation

Segmento: HealthcareLegend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Análise Ranking Invest

Valor de Mercado
$ 4.31 Bi
IVR
-0.09Índice proprietário de comparação relativa: -0,09.
IVR2
-0.33Leitura proprietária complementar: -33%.
MLL
-0.33Leitura proprietária complementar: -33%.
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 1.02 Bi

Dívida Líquida

-$ 78.89 Mi

L4T

-$ 218.15 Mi

MM4T

-31.41%

Indicadores Básicos

ROE

-21.43%

Índices de Previsibilidade

Receita Líquida

G1.68

Lucro

D0.51

Margem

D0.79

Índices de Tendência

Receita Líquida

A10.76

Lucro

C3.42

Margem

A9.61

Índices de Endividamento

DIV/PAT

-0.08

DIV/L4T

0.36

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.